Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment


Journal

Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585

Informations de publication

Date de publication:
01 Dec 2023
Historique:
accepted: 17 07 2023
medline: 4 12 2023
pubmed: 2 12 2023
entrez: 1 12 2023
Statut: epublish

Résumé

Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that develop postnatally in non-lymphoid tissues and are associated with pathological conditions. TLS typically comprise B-cell follicles containing and are encompassed by T- cell zones and dendritic cells. The prognostic and predictive value of TLS in the tumor microenvironment (TME) as potential mediators of antitumor immunity have gained interest. However, the precise relationship between localization and maturation of TLS and the clinical outcome of their presence in clear cell renal cell carcinoma (ccRCC) is yet to be elucidated. Immunohistochemistry and multispectral fluorescence were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. A thorough investigation of the prognostic implications of the TLS heterogeneity in 395 patients with ccRCC from two independent cohorts was conducted. Associations between TLS heterogeneity and immunologic activity were assessed by quantifying the immune cell infiltration. Infiltrated TLS were identified in 34.2% of the ccRCC samples (N=395). These TLS were found to be tumor-proximal, tumor-distal, or both in 37.8%, 74.1%, and 11.9% of the TLS-positive cases, respectively. A higher proportion of early TLS was found in tumor-distal TLS (p=0.016), while tumor-proximal TLS primarily comprised secondary follicle-like structures (p=0.004). In the main study cohort (Fudan University Shanghai Cancer Center, N=290), Kaplan-Meier analyses revealed a significant correlation between the presence of tumor-proximal TLS and improved progression-free survival (PFS, p<0.001) and overall survival (OS, p=0.002). Conversely, the presence of tumor-distal TLS was associated with poor PFS (p=0.02) and OS (p=0.021). These findings were further validated in an external validation set of 105 patients with ccRCC. Notably, the presence of mature TLS (namely secondary follicle-like TLS, with CD23 This study for the first time elucidates the impact of TLS localization and maturation heterogeneities on the divergent clinical outcomes of ccRCC. The findings reveal that most TLS in ccRCC are located in the tumor-distal area and are associated with immature, immunosuppressive characterizations. Furthermore, our findings corroborate previous research demonstrating that tumor-proximal TLS were associated with favorable clinical outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that develop postnatally in non-lymphoid tissues and are associated with pathological conditions. TLS typically comprise B-cell follicles containing and are encompassed by T- cell zones and dendritic cells. The prognostic and predictive value of TLS in the tumor microenvironment (TME) as potential mediators of antitumor immunity have gained interest. However, the precise relationship between localization and maturation of TLS and the clinical outcome of their presence in clear cell renal cell carcinoma (ccRCC) is yet to be elucidated.
METHODS METHODS
Immunohistochemistry and multispectral fluorescence were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. A thorough investigation of the prognostic implications of the TLS heterogeneity in 395 patients with ccRCC from two independent cohorts was conducted. Associations between TLS heterogeneity and immunologic activity were assessed by quantifying the immune cell infiltration.
RESULTS RESULTS
Infiltrated TLS were identified in 34.2% of the ccRCC samples (N=395). These TLS were found to be tumor-proximal, tumor-distal, or both in 37.8%, 74.1%, and 11.9% of the TLS-positive cases, respectively. A higher proportion of early TLS was found in tumor-distal TLS (p=0.016), while tumor-proximal TLS primarily comprised secondary follicle-like structures (p=0.004). In the main study cohort (Fudan University Shanghai Cancer Center, N=290), Kaplan-Meier analyses revealed a significant correlation between the presence of tumor-proximal TLS and improved progression-free survival (PFS, p<0.001) and overall survival (OS, p=0.002). Conversely, the presence of tumor-distal TLS was associated with poor PFS (p=0.02) and OS (p=0.021). These findings were further validated in an external validation set of 105 patients with ccRCC. Notably, the presence of mature TLS (namely secondary follicle-like TLS, with CD23
CONCLUSION CONCLUSIONS
This study for the first time elucidates the impact of TLS localization and maturation heterogeneities on the divergent clinical outcomes of ccRCC. The findings reveal that most TLS in ccRCC are located in the tumor-distal area and are associated with immature, immunosuppressive characterizations. Furthermore, our findings corroborate previous research demonstrating that tumor-proximal TLS were associated with favorable clinical outcomes.

Identifiants

pubmed: 38040418
pii: jitc-2023-006667
doi: 10.1136/jitc-2023-006667
pmc: PMC10693897
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Cancer Res Clin Oncol. 2019 Jun;145(6):1377-1385
pubmed: 30963235
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Nat Med. 2020 Dec;26(12):1839-1844
pubmed: 33046870
Int J Biol Sci. 2021 Jun 1;17(9):2205-2222
pubmed: 34239350
J Immunol. 2013 Aug 15;191(4):2001-8
pubmed: 23825314
Cancers (Basel). 2021 Nov 22;13(22):
pubmed: 34831009
Nature. 2020 Apr;580(7801):E1
pubmed: 32238929
J Immunother Cancer. 2022 Dec;10(12):
pubmed: 36549781
Front Cell Dev Biol. 2021 Dec 06;9:785410
pubmed: 34938737
Cell Mol Immunol. 2020 Jun;17(6):570-575
pubmed: 32415259
Immunity. 2022 Mar 8;55(3):527-541.e5
pubmed: 35231421
Cancer Immunol Immunother. 2019 Nov;68(11):1733-1745
pubmed: 31598757
J Immunol. 2009 Mar 1;182(5):3310-7
pubmed: 19234230
Cancer Invest. 2023 Jan;41(1):48-57
pubmed: 36239379
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
JAMA Oncol. 2019 Mar 1;5(3):411-421
pubmed: 30476955
Lancet. 2009 Mar 28;373(9669):1119-32
pubmed: 19269025
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cancers (Basel). 2022 Dec 12;14(24):
pubmed: 36551593
Cancer Cell. 2023 Jan 9;41(1):139-163.e17
pubmed: 36563681
Oncoimmunology. 2015 Feb 03;4(1):e985082
pubmed: 25949868
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Cancer Cell. 2021 May 10;39(5):632-648.e8
pubmed: 33711273
Nat Commun. 2021 Jul 5;12(1):4127
pubmed: 34226552
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Nat Commun. 2022 Apr 19;13(1):2052
pubmed: 35440542
Nat Commun. 2022 Dec 5;13(1):7494
pubmed: 36470859
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35314433
Cancer. 2009 May 15;115(10 Suppl):2282-9
pubmed: 19402071
Histopathology. 2002 Oct;41(4):283-300
pubmed: 12383210
J Immunother Cancer. 2023 Feb;11(2):
pubmed: 36759015
Int J Biol Sci. 2022 Jul 18;18(13):4884-4900
pubmed: 35982911
J Hepatol. 2019 Jan;70(1):58-65
pubmed: 30213589
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Front Immunol. 2022 Aug 01;13:953721
pubmed: 35979371
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
Nat Commun. 2022 Sep 14;13(1):5378
pubmed: 36104359
Oncoimmunology. 2017 Dec 18;7(2):e1378844
pubmed: 29416939
Science. 2022 Jan 07;375(6576):eabf9419
pubmed: 34990248
Cancer Cell. 2021 May 10;39(5):662-677.e6
pubmed: 33861994
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Nat Cancer. 2021 Aug;2(8):794-802
pubmed: 35118423
J Immunother Cancer. 2022 Jul;10(7):
pubmed: 35863822
Nat Immunol. 2017 Nov;18(11):1207-1217
pubmed: 28892469
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397
Front Immunol. 2021 Jun 30;12:698604
pubmed: 34276690
Cancer Immunol Immunother. 2021 Oct;70(10):3001-3013
pubmed: 34259900

Auteurs

Wenhao Xu (W)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.

Jiahe Lu (J)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.
School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Wang-Rui Liu (WR)

Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

Aihetaimujiang Anwaier (A)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.

Yuhao Wu (Y)

Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.

Xi Tian (X)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.

Jia-Qi Su (JQ)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.

Yuan-Yuan Qu (YY)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China dingwei_ye@fudan.edu.cn zhanghl918@alu.fudan.edu.cn yangjianfeng@shutcm.edu.cn quyy1987@163.com.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.

Jianfeng Yang (J)

Department of Surgery, ShangNan Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China dingwei_ye@fudan.edu.cn zhanghl918@alu.fudan.edu.cn yangjianfeng@shutcm.edu.cn quyy1987@163.com.

Hailiang Zhang (H)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China dingwei_ye@fudan.edu.cn zhanghl918@alu.fudan.edu.cn yangjianfeng@shutcm.edu.cn quyy1987@163.com.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.

Dingwei Ye (D)

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China dingwei_ye@fudan.edu.cn zhanghl918@alu.fudan.edu.cn yangjianfeng@shutcm.edu.cn quyy1987@163.com.
Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH